The kinetics and inhibition by 3'-azido-3'-de oxythymidine triphosphate (AZT-TP) of reverse transcriptase (RT) from paired AZT-suscepti ble and -resistant primary isolates of HIV-1 taken from patients before and after therapy were examined in vitro. The resistant isolates showed mutations in the RT at positions 67, 70,215 and 219, and also in one case at positions 41 and 215. No changes in the V m ax , the K m for dTTP or the K; for AZT-TP of a magnitude sufficient to account for the observed development of resistance to AZT in primary isolates from these patients were found.
Introduction
3'-Azido-3'-deo xythymidine (AZT) is a thymidine analogue that is phosphorylated intracellularly to the triphosphate by enzymes of the thymidine salvage pathway. The triphosphate of AZT, AZT-TP, inhibits the reverse transcriptase (RT) of human immunodeficie ncy virus type 1 (HIV-1) by chain termination, since AlT lacks the 3'hydroxyl group necessary for further DNA chain elongation (Furman et al., 1986) .
Long-term therapy with AZT often leads to the development of resistant virus (Larder and Kemp, 1989; Larder et al., , 1990 Rooke et sl., 1989; Kellam et al., 1992 Kellam et al., , 1994 Wahlberg et al., 1992) . The development of resistance to AZT has been shown to be associated with the appearance of specific mutations at at least five positions in the RT, namely, at amino acids 41 (L), 67 (N), 70 (R), 215 (Y or F) and 219 (Q) (Larder and Kemp, 1989; Larder et al., 1991; S1. Clair et al., 1991; Boucher et al., 1992; Kellam et al., 1992; Larder, 1992; Wahlberg et al., 1992) .
However, the effects of these mutations on the catalytic mechanism of RT and its susceptibility to inhibition by AZT-TP are unclear. Several studies on RT with mutations at positions 67,70,215 and 219 have consistently failed to show changes in kinetics or susceptibility to AZT-TP sufficient to account for the effects of these mutations on the sensitivity of the virus to AZT (Larder and Kemp, 1989; Dianzani et al., 1992; Lacey et el., 1992; Eron et al., 1993; Carroll et al., 1994) .
These results are in apparent conflict with the proposed mechanism of action of AZT, that is, inhibition of the RT by AZT-TP. It has been suggested that RT carrying AZTresistance mutations could exhibit conformational heterogeneity which is not preserved during purification procedures, resulting in the selection of incorrect or inappropriate conformations of the enzyme (Wilson et al., 1994) .
We examined the kinetics and inhibition of RT from paired primary isolates of HIV-1 taken from patients before and after treatment with AZI. RT was prepared directly from primary cultures of HIV-1 in peripheral blood mononuclear cells (PBMC) without selection. We included one isolate showing the 41L mutation, which has not previously been studied for its effect upon RT.
Results and conclusions

Biological characterizatio n of the isolates
The biological characterizatio n of the isolates is shown in Table 1 . Isolates 689 + 2441 and isolates 720 + 2748 were paired isolates taken from two patients before and after therapy with AZT, respectively. The two posttherapy isolates from these patients (2441 and 2748) contained mutations at positions 67, 70, 215 and 219, and had ICsos for AZT 100-fold higher than the corresponding pre-therapy isolates. Isolate 5540 was taken after AZT therapy from a third patient and showed mutations at positions 41 and 215.
Kinetics of inhibition of RT from the isolates
The kinetics of inhibition by AZT-TP of RT from the five isolates was analysed and the results are summarized in Table 1 . The V max and the «; for dTIP of the RTs from the different primary isolates were similar. There was no pattern of change in the V max, K m for dTIP, or efficiency (Vma,/K m) of the RTs tested that could be reasonably linked to the mutations present.
The K, for AZT-TP for the different RTs varied from 0.052 to 0.1 IlM. The K, for AZT-TP for RT from the AZTresistant virus isolates was similar to that from the paired AZT-susceptible virus isolates from the same patient. The ratio of Km(dTIP):K,(AZT-TP), which indicates the relative affinity of the enzymes for dTIP and AZT-TP, was similar for the paired isolates, indicating that the ability of RT to discriminate between the natural substrate dTIP and AZT-TP did not vary greatly between the isolates. RT from isolate 5540, containing both the 41Land 215Y mutations, showed an affinity for AZT-TP identical to that of the pre-therapy isolates from the other two patients (689 and 720).
The values for the kinetic parameters presented here are comparable to those published earlier for native purified RT (Furman et a/., 1986; St. Clair et a/., 1987) or cloned purified RT (Larder and Kemp, 1989; Pokholok et sl., 1993) . Previous data have indicated that purification of recombinantly expressed mutant RT may select for aberrant conformations of the enzyme which thus do not show the changes in kinetics expected to accompany AZT resistance (Wilson et a/., 1994) . We did not purify RT for these studies,' but used pelleted virions from primary PBMC cultures as the source of enzyme. Furthermore, we also directly compared paired primary virus isolates taken from the same patients before and after AZT therapy. We did not see changes in either the V max, the K m for dTIP or the K, for AZT-TP in RT from the post-therapy resistant virus isolates of a magnitude sufficient to account for the change in the sensitivity of the patient's virus to AZT observed in cell culture.
We also included in our study one isolate containing mutations at positions 41 and 215 of RT. These mutations cause a large change in the sensitivity to AZT, and seem to have a stabilizing effect on the RT structure . Earlier failures to show resistance of RT to AZT-TP could have resulted from the lack of the 41L mutation. However, even this enzyme failed to show any major change in kinetics or inhibition by AZT-TP. It must, however, be pointed out that we did not have available an isolate from this patient taken before therapy for comparison.
The assay we used for this kinetic analysis is commonly used for analysis of the function of polymerases of various kinds. It is, however, far from natural, and it might be suspected that the failure to show changes in the kinetics of RT from AZT-resistant virus is caused by artifacts in the assay employed. On the other hand, using similar assays it has been possible to show changes in the sensitivity to ddATP and 2',3'-dideoxy-5-fluoro-3'-thiacytidine triphosphate (FTC-TP) of RT from virus resistant to ddl and FTC, respectively (Martin et a/., 1993; Schinazi et a/., 1993) .
Thus, for AZT there does not appear to be a simple correlation between the sensitivity of the viral isolates to AZT as measured in cell culture and the sensitivity of RTs from those isolates to AZT-TP as measured in an in vitro enzyme assay using an artificial template. Whether the discrepancy is a result of the RT assay or the cell culture, or both, is not yet clear.
The precise effect of the AZT-resistance mutations (if any) upon the kinetic mechanism of RT therefore remains to be determined. Recent evidence suggests that the effect of mutation at position 74 of the RT, which is associated with resistance to ddl, might be to disturb the interaction of the enzyme with the template (Boyer et al., 1994) . Such a mechanism might also operate for muta- (Pokholok et al., 1993) .
In conclusion, using RT from paired primary isolates (including one bearing the 41 L mutation) without selection or purification, we have not found differences in the affinity for AZT-TP sufficient to account in a simple way for the observed development of resistance to AZT in these virus isolates. Further work is required to reveal the effects and significance of these AZT-resistance mutations for the function of RT. In view of these and other data, it must also be considered that our present view of the mechanism of action of AZT is incomplete and may need to be revised.
Materials and Experimental Procedures
Primary HIV-1 isolates Peripheral blood mononuclear cells (PBMC) from healthy HIV-1 seronegative blood donors were obtained by Ficoll-Paque centrifugation and incubated in RPMI1640 with 10% heat-inactivated fetal calf serum. Primary iSOla!~of HIV-1 were made by co-cultivation of infected patient P!:JMC with phytohaemagglutinin (PHA)-stimulated fresh donor PBMC in the presence of IL-2 as previously described (Albert and Fenyo, 1990) . Isolates were frozen at -70°C for later use.
Characterization of the isolates
The sensitivity of the isolates to AZT was tested in PBMC as previously described (Cox et al., 1994) . Briefly, 50000 PBMC in microtitre plates were infected with the viral isolates (10-50 TCID so) in the presence of different concentrations of AZT. After 7 days at 37°C, the supernatants were tested for viral growth in a p24 ELISA (Sundqvist et al., 1989) . RT from the primary isolates was also directly sequenced using nested primers (Albert and Fenyo, 1990; Albert et al., 1992; Wahlberg et al., 1992) . The development of AZT resistance during therapy and the appearance of AZT-resistance mutations in two of the patients have been previously described .
Preparation of RT enzyme
Frozen isolates were thawed and used to infect fresh PHAstimulated PBMC in the presence of IL-2. At the peak of antigen production, supernatants were harvested and cell-free virus sedimented by centrifugation at 132000 gfor 90 min. Viral pellets were redissolved in lysis buffer (50 mM Tris-HCI, pH 7.6, 35mM KCI, 4mM dithiolthreitol, 1 mM EDTA and 1.3% Triton X100) and frozen in aliquots for later use.
Reverse transcriptase assay
RT activity was assayed in microtitre plates as previously described (Vrang and Oberg, 1986; Vrang et al., 1987) . The assay mixture contained (in a total volume of 100 Ill): 50 mM Tris-HCI, pH 8.0; 50 mM KCI; 4 mM dithiothreitol; 6 mM MgCI 2;
Reverse transcriptase from AZT-resistant HIV-1 125 50119 bovine serum albumin fraction V; 11lg (rA)n (dT)12-18 (Pharmacia Biotechnology, Sollentuna, Sweden); and [3H]_ dTTP (Amersham International, Amersham, UK) from 0.5-5 11M (specific activity, 2.0-0.41 x 10 8 dpm/nmol). The reaction was started by addition of 40 III of diluted viral lysate in the presence or absence of AZT-TP and the plates were incubated . at 37°C for 90 min. The reaction was stopped and the products precipitated by addition of 100 III ice-cold 5% trichloroacetic acid (TCA). The products were filtered onto pre-printed filter papers using a cell harvester (Skatron, Norway) and the filter papers were washed four times in ice-cold 5% TCA with 0.02 M pyrophosphate and then once in 95% ethanol. After drying at 37°C for 30 min, scintillant was added and the filters were counted in a 1205 Betaplate scintillation counter (LKB Wallac, Finland). For each of the enzyme preparations, the reaction was linear with respect to time at least up to 180 min, and also with respect to dilution of the enzyme. Experiments were performed under first-order conditions.
Calculation of results
Experiments were performed in duplicate. The rate of the reaction (V) was calculated from the mean cpm and is expressed as nmol of dTTP incorporated into the primer per minute per pg of p24 protein in the viral lysate. The p24 protein content of the viral Iysates was measured in a sensitive ELISA (Sundqvist et al., 1989) , since the virallysates contained too little protein for measurement using standard protein assays. V max , K m and K;
values were determined from the slopes and intercepts of the Lineweaver-Burk plots and are given as the mean value ± standard deviation of two independent experiments.
